Lung Cancer

Panelists discuss how comprehensive biomarker testing in early-stage disease settings provides crucial molecular insights that guide surgical planning and inform critical decisions about neoadjuvant, perioperative, and adjuvant treatment strategies.

Pembrolizumab/chemotherapy was approved by Health Canada for the treatment of patients with unresectable advanced or metastatic pleural mesothelioma.

Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.

Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.

Isabel Preeshagul, DO, MBS, discusses frontline treatment selection for patients with SCLC and significant FDA approvals in this disease.

Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.

Enhanced dermatologic management lowered rates of dermatologic AEs during first-line amivantamab/lazertinib treatment for EGFR-mutated advanced NSCLC.

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

Tarlatamab improved overall survival vs chemotherapy in small cell lung cancer following progression on or after platinum-based chemotherapy.

Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

Osimertinib plus Dato-DXd elicits responses in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib.

Subcutaneous and intravenous pembrolizumab provided comparable efficacy and safety in patients with previously untreated, metastatic non–small cell lung cancer.

Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.

Savolitinib plus osimertinib produced responses in pretreated MET-amplified or -overexpressed advanced non–small cell lung cancer harboring EGFR mutations.

The European Commission has approved subcutaneous amivantamab in multiple indications in advanced EGFR-mutant non–small cell lung cancer.

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.

Updated KEYNOTE-799 data continued to show robust activity with pembrolizumab plus concurrent chemoradiation in unresectable stage III NSCLC.

Longer-term outcomes from LAURA further support the benefit of osimertinib over placebo for patients with unresectable stage III EGFR-mutated NSCLC.

CAN-2049 plus prodrug and continued immune checkpoint inhibition showed a potential OS benefit in advanced non–small cell lung cancer.

The EMA’s CHMP recommended the approval of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer.

Panelists discuss how medical professionals consider continuing osimertinib with second-line and subsequent therapies based on disease progression, resistance mechanisms, and patient response. It may be combined with other agents or switched depending on clinical trials, biomarkers, and overall treatment goals to optimize outcomes.

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.